

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

IntegraGen reports sales of € 4.2 million in the first half of 2019, up 15%

- Strong increase in sequencing services, primarily related to the launch of SeqOIA sequencing platform
- Strong sales growth for MERCURY® and SIRIUS® sequencing data interpretation software

Evry, France (July 11, 2019) - IntegraGen (FR0010908723 - ALINT - Eligible PEA PME), a company specializing in the decoding of the human genome, which carries out interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools in oncology, today announced its unaudited revenue for the first half of 2019.

Revenues amounted to 4,168 K€ compared to 3,624 K€ in the first half of 2018, an increase of 15%.

Sales growth was primarily related to initial revenue generated by SeqOIA's Cooperative Health Group (GCS) Sequencing Platform, of which IntegraGen is the industrial partner for the sequencing portion. As noted previously, this service contract covers the period from January 1, 2019 to December 31, 2023 and represents a minimum commitment of 16.4 M€ and a maximum of 25.6 M€ over the duration of the contract.

Sales of software and consulting services increased by 38%.

<i>in thousand EUROS</i>	S1 2019	S1 2018	Var. '19 vs. '18
Total operating revenues	4 168	3 624	+15%
Sequencing services	3 793	3 356	437
Interpretation software and consulting	313	227	86
Diagnostic	62	40	22

Outlook for 2019: Strong Growth Confirmed

The SeqOIA project, whose services have been invoiced since January 2019, will generate a turnover of at least 2,013 K€ in 2019 and the company anticipates strong revenue growth for the year.

The company's new competitive sequencing offers also make it possible to anticipate a good growth of the services performed on behalf of laboratories.

Lastly, in line with the first half of the year, the company is also expecting sales of sequencing data interpretation software (SIRIUS® and MERCURY®) in Software as a Service (SaaS) mode.

Bernard Courtieu, IntegraGen's Chairman and CEO, commented, "*The figures for the first half of 2019 confirm the significant growth of IntegraGen's business, which is now benefiting from the impact of sequencing activities carried out for the SeqOIA platform. We are actively pursuing the development of new offerings in genomics activities and are conducting a sustained commercial effort in sequencing services as well as in interpretation tools. Sales growth and refinement of our processes allow us to continue to improve operational profitability.*"

The financial results for the first half of 2019 will be published on September 23, 2019 (before opening of the financial markets).

About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2018, IntegraGen had 44 employees and generated revenue of 6.9 M€ in 2018. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com



CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53